NCT06840080

OEA and LipiSperse Metabolic Study

Short-term Effect of Oleoylethanolamide (OEA) and LipiSperse Supplementation on Metabolic Pathways in Otherwise Healthy Participants - a Single Blind, Cross-over Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Accepted

Summary

A placebo controlled, single blind, cross-over study evaluating the short-term effect of oleoylethanolamide (OEA) with LipiSperse supplementation on metabolic pathways in healthy participants.

Detailed description

This study aims to compare the metabolic effects of two different doses of OEA with LipiSperse to a placebo in healthy participants over an 8-hour period. There are three trial arms in this study. Each participant will complete all 3 arms of the study, for a 3-way cross-over.

Conditions

• Healthy Volunteers - Male and Female
• Pharmacokinetic Study in Healthy Volunteers

Interventions

Type	Name	Description
OTHER	Placebo	Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules
DIETARY_SUPPLEMENT	125mg OEA with LipiSperse	Single dose of 2 capsules. 1 capsule contains 125mg of OEA and 13.9mg of LipiSperse, the other capsule is a placebo.
DIETARY_SUPPLEMENT	250mg OEA with LipiSperse	Single dose of 2 capsules. Each capsule contains 125mg of OEA and 13.9mg of LipiSperse.

Timeline

• Start date: 2025-03-04
• Primary completion: 2025-06-04
• Completion: 2025-06-04
• First posted: 2025-02-21
• Last updated: 2025-11-18

Locations

1 site across 1 country: Australia